HIV-1感染个体脑脊液和血液中的达芦那韦浓度。
Darunavir concentrations in cerebrospinal fluid and blood in HIV-1-infected individuals.
作者信息
Yilmaz Aylin, Izadkhashti Arash, Price Richard W, Mallon Patrick W, De Meulder Marc, Timmerman Philip, Gisslén Magnus
机构信息
Department of Infectious Diseases, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
出版信息
AIDS Res Hum Retroviruses. 2009 Apr;25(4):457-61. doi: 10.1089/aid.2008.0216.
Abstract
Darunavir is the most recently licensed protease inhibitor currently used in treatment-experienced HIV-infected individuals. Our objective was to determine darunavir concentrations in cerebrospinal fluid (CSF) and plasma in subjects receiving antiretroviral treatment regimens containing ritonavir-boosted darunavir. Darunavir concentrations were determined by liquid chromatography tandem mass spectrometry in 14 paired CSF and plasma samples from eight HIV-1-infected individuals. The lower limit of quantification was 5.0 ng/ml. All of the 14 CSF samples had detectable darunavir concentrations with a median darunavir concentration of 34.2 ng/ml (range 15.9-212.0 ng/ml). The median (range) plasma darunavir concentration was 3930 (1800-12900) ng/ml. All CSF samples had detectable darunavir concentrations. Most of them exceeded or were in the same range as levels needed to inhibit replication of wild type virus, making it probable that darunavir, at least to some extent, contributes to the suppression of HIV replication in the central nervous system.
摘要
地瑞那韦是目前用于接受过治疗的HIV感染者的最新获批的蛋白酶抑制剂。我们的目的是确定接受含利托那韦增强的地瑞那韦抗逆转录病毒治疗方案的受试者脑脊液（CSF）和血浆中的地瑞那韦浓度。通过液相色谱串联质谱法测定了来自8名HIV-1感染者的14对脑脊液和血浆样本中的地瑞那韦浓度。定量下限为5.0 ng/ml。14份脑脊液样本中均检测到地瑞那韦浓度，地瑞那韦浓度中位数为34.2 ng/ml（范围15.9 - 212.0 ng/ml）。血浆地瑞那韦浓度中位数（范围）为3930（1800 - 12900）ng/ml。所有脑脊液样本均检测到地瑞那韦浓度。其中大多数超过或处于抑制野生型病毒复制所需水平的相同范围内，这使得地瑞那韦至少在一定程度上有助于抑制中枢神经系统中的HIV复制成为可能。
相似文献
1
Darunavir concentrations in cerebrospinal fluid and blood in HIV-1-infected individuals.HIV-1感染个体脑脊液和血液中的达芦那韦浓度。
AIDS Res Hum Retroviruses. 2009 Apr;25(4):457-61. doi: 10.1089/aid.2008.0216.
2
Darunavir concentrations in CSF of HIV-infected individuals when boosted with cobicistat versus ritonavir.当使用考比司他与利托那韦增强时，HIV 感染者脑脊液中的达芦那韦浓度。
J Antimicrob Chemother. 2017 Sep 1;72(9):2574-2577. doi: 10.1093/jac/dkx165.
3
Cerebrospinal fluid HIV-1 RNA during treatment with ritonavir/saquinavir or ritonavir/saquinavir/stavudine.使用利托那韦/沙奎那韦或利托那韦/沙奎那韦/司他夫定治疗期间的脑脊液HIV-1 RNA
AIDS. 2000 Jul 28;14(11):1583-9. doi: 10.1097/00002030-200007280-00014.
4
The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.核苷类药物节省型抗逆转录病毒疗法对1型人类免疫缺陷病毒（HIV-1）感染患者中利托那韦增强型达芦那韦药代动力学的影响。
Antivir Ther. 2010;15(2):213-8. doi: 10.3851/IMP1517.
5
Determinants of darunavir cerebrospinal fluid concentrations: impact of once-daily dosing and pharmacogenetics.达芦那韦脑脊液浓度的决定因素：每日一次给药和药物遗传学的影响。
AIDS. 2012 Jul 31;26(12):1529-33. doi: 10.1097/QAD.0b013e3283553619.
6
Effect of protein binding on unbound atazanavir and darunavir cerebrospinal fluid concentrations.蛋白结合对阿扎那韦和达芦那韦游离脑脊液浓度的影响。
J Clin Pharmacol. 2014 Sep;54(9):1063-71. doi: 10.1002/jcph.298. Epub 2014 Apr 8.
7
Interindividual and intra-individual variabilities of darunavir and ritonavir plasma trough concentrations in multidrug experienced HIV patients receiving salvage regimens.多药耐药的 HIV 患者接受挽救性治疗方案时，达芦那韦和利托那韦血药谷浓度的个体间和个体内变异性。
Ther Drug Monit. 2013 Dec;35(6):785-90. doi: 10.1097/FTD.0b013e31829ad690.
8
Darunavir, ritonavir, and etravirine pharmacokinetics in the cervicovaginal fluid and blood plasma of HIV-infected women.达芦那韦、利托那韦和依曲韦林在感染 HIV 的女性的宫颈阴道分泌物和血浆中的药代动力学。
Antimicrob Agents Chemother. 2011 Mar;55(3):1120-2. doi: 10.1128/AAC.00889-10. Epub 2010 Dec 20.
9
Antiviral activity and CSF concentrations of 600/100 mg of darunavir/ritonavir once daily in HIV-1 patients with plasma viral suppression.每日一次服用600/100毫克达芦那韦/利托那韦对血浆病毒得到抑制的HIV-1患者的抗病毒活性及脑脊液浓度
J Antimicrob Chemother. 2015 May;70(5):1513-6. doi: 10.1093/jac/dku558. Epub 2015 Jan 20.
10
Decreased plasma levels of darunavir/ritonavir in a vertically infected pregnant woman carrying multiclass-resistant HIV type-1.一名携带多类耐药1型艾滋病毒的垂直感染孕妇体内达芦那韦/利托那韦的血浆水平降低。
Antivir Ther. 2010;15(1):127-9. doi: 10.3851/IMP1473.
引用本文的文献
1
Darunavir Nanoformulation Suppresses HIV Pathogenesis in Macrophages and Improves Drug Delivery to the Brain in Mice.达芦那韦纳米制剂可抑制巨噬细胞中的HIV发病机制，并改善药物向小鼠脑部的递送。
Pharmaceutics. 2024 Apr 19;16(4):555. doi: 10.3390/pharmaceutics16040555.
2
Central nervous system disorders after use of dolutegravir: evidence from preclinical and clinical studies.使用度鲁特韦后的中枢神经系统疾病：来自临床前和临床研究的证据。
Pharmacol Rep. 2023 Oct;75(5):1138-1151. doi: 10.1007/s43440-023-00515-y. Epub 2023 Aug 21.
3
Selection of HIV-1 for resistance to fifth-generation protease inhibitors reveals two independent pathways to high-level resistance.HIV-1 对第五代蛋白酶抑制剂耐药性的选择揭示了两种独立的高耐药水平的途径。
Elife. 2023 Mar 15;12:e80328. doi: 10.7554/eLife.80328.
4
Luminescent PLGA Nanoparticles for Delivery of Darunavir to the Brain and Inhibition of Matrix Metalloproteinase-9, a Relevant Therapeutic Target of HIV-Associated Neurological Disorders.载阿扎那韦的发光 PLGA 纳米粒递药系统通过抑制基质金属蛋白酶-9 治疗 HIV 相关神经障碍
ACS Chem Neurosci. 2021 Nov 17;12(22):4286-4301. doi: 10.1021/acschemneuro.1c00436. Epub 2021 Nov 2.
5
Anti-HIV Activity of Cucurbitacin-D against Cigarette Smoke Condensate-Induced HIV Replication in the U1 Macrophages.葫芦素-D 抗香烟烟雾凝聚物诱导 U1 巨噬细胞中 HIV 复制的活性。
Viruses. 2021 May 27;13(6):1004. doi: 10.3390/v13061004.
6
Efficacy, pharmacokinetics and neurocognitive performance of dual, NRTI-sparing antiretroviral therapy in acute HIV-infection.在急性 HIV 感染中，双重、非核苷类逆转录酶抑制剂节省型抗逆转录病毒疗法的疗效、药代动力学和神经认知表现。
AIDS. 2020 Nov 1;34(13):1923-1931. doi: 10.1097/QAD.0000000000002652.
7
Pharmacokinetics and antiviral activity of cabotegravir and rilpivirine in cerebrospinal fluid following long-acting injectable administration in HIV-infected adults.长效注射给药后 HIV 感染成人的脑脊液中卡替拉韦和利匹韦林的药代动力学和抗病毒活性。
J Antimicrob Chemother. 2020 Mar 1;75(3):648-655. doi: 10.1093/jac/dkz504.
8
Harnessing nanostructured systems for improved treatment and prevention of HIV disease.利用纳米结构系统改善艾滋病的治疗与预防
Bioeng Transl Med. 2018 Jul 27;3(2):102-123. doi: 10.1002/btm2.10096. eCollection 2018 May.
9
Direct injection HILIC-MS/MS analysis of darunavir in rat plasma applying supported liquid extraction.采用支撑液液萃取法对大鼠血浆中达芦那韦进行直接进样亲水相互作用色谱-串联质谱分析。
J Pharm Anal. 2015 Feb;5(1):43-50. doi: 10.1016/j.jpha.2014.05.001. Epub 2014 May 20.
10
Differential Effects of Antiretroviral Drugs on Neurons In Vitro: Roles for Oxidative Stress and Integrated Stress Response.抗逆转录病毒药物对体外神经元的影响差异：氧化应激和综合应激反应的作用。
J Neuroimmune Pharmacol. 2018 Mar;13(1):64-76. doi: 10.1007/s11481-017-9761-6. Epub 2017 Aug 31.
本文引用的文献
1
Report from the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy.
AIDS Clin Care. 2007 Nov;19(11):99-100.
2
Immune activation of the central nervous system is still present after >4 years of effective highly active antiretroviral therapy.在接受高效抗逆转录病毒治疗4年以上后，中枢神经系统的免疫激活仍然存在。
J Infect Dis. 2007 Dec 15;196(12):1779-83. doi: 10.1086/523648.
3
Persistent intrathecal immune activation in HIV-1-infected individuals on antiretroviral therapy.接受抗逆转录病毒治疗的HIV-1感染者鞘内持续免疫激活。
J Acquir Immune Defic Syndr. 2008 Feb 1;47(2):168-73. doi: 10.1097/QAI.0b013e31815ace97.
4
Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial.在TITAN研究中，接受过治疗的HIV感染患者中，达芦那韦-利托那韦与洛匹那韦-利托那韦相比在48周时的疗效和安全性：一项随机对照III期试验
Lancet. 2007 Jul 7;370(9581):49-58. doi: 10.1016/S0140-6736(07)61049-6.
5
The role of compartment penetration in PI-monotherapy: the Atazanavir-Ritonavir Monomaintenance (ATARITMO) Trial.房室渗透在蛋白酶抑制剂单药治疗中的作用：阿扎那韦-利托那韦单药维持治疗（ATARITMO）试验
AIDS. 2007 Jun 19;21(10):1309-15. doi: 10.1097/QAD.0b013e32814e6b1c.
6
Elevated cerebrospinal fluid neurofilament light protein concentrations predict the development of AIDS dementia complex.脑脊液神经丝轻链蛋白浓度升高可预测艾滋病痴呆综合征的发生。
J Infect Dis. 2007 Jun 15;195(12):1774-8. doi: 10.1086/518043. Epub 2007 May 2.
7
Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials.达芦那韦-利托那韦在POWER 1和2研究中对经治HIV-1感染患者48周时的疗效和安全性：两项随机试验数据的汇总亚组分析
Lancet. 2007 Apr 7;369(9568):1169-78. doi: 10.1016/S0140-6736(07)60497-8.
8
9
Treatment benefit on cerebrospinal fluid HIV-1 levels in the setting of systemic virological suppression and failure.在全身病毒学抑制和失败的情况下，治疗对脑脊液中HIV-1水平的益处。
J Infect Dis. 2006 Dec 15;194(12):1686-96. doi: 10.1086/508750. Epub 2006 Nov 3.
10
Cerebrospinal fluid HIV-1 infection usually responds well to antiretroviral treatment.脑脊液HIV-1感染对抗逆转录病毒治疗通常反应良好。
Antivir Ther. 2005;10(6):701-7.
Zotero 插件